Asymchem Laboratories (Tianjin) Co., Ltd. (Stock Code: 6821) reported total operating revenue of RMB4.63 billion for the first three quarters of 2025, an 11.82% increase year-on-year. Net profit attributable to shareholders reached RMB800 million, reflecting 12.66% growth over the same period last year.

The small molecule business maintained stable performance, while emerging segments such as peptides, oligonucleotides, and antibody-drug conjugates (ADCs) showed strong momentum, with emerging business revenue surging by 71.87%. Revenue from the chemical macromolecule category climbed over 150% year-on-year. Revenue from multinational pharmaceutical companies was RMB2.05 billion, up 1.98%, and revenue from small and medium-sized pharmaceutical companies was RMB2.58 billion, up 21.14%. The overall gross profit margin stood at 42.44%, driven by higher capacity utilization in the emerging business. The company anticipates full-year revenue growth of 13% to 15%, supported by a higher delivery schedule in the fourth quarter.